PDS Biotechnology Corp expected to post a loss of 31 cents a share - Earnings Preview

PDS Biotechnology

12/05/2023 19:18

* PDS Biotechnology Corp  PDSB.OQ   PDSB.O  is expected
to show no
change in quarterly revenue when it reports  results on May 15. 
    * 
    * ​Refinitiv's mean analyst estimate for PDS Biotechnology
Corp is
for a loss of 31 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 1.2%
in the last three months. ​
    * Wall Street's median 12-month price target for PDS
Biotechnology
Corp is $18​, above​ its last closing price of $6.71. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022              -0.29      -0.67     Missed  -133.3
 Sep. 30 2022  -0.28       -0.28      -0.26     Beat    7.6
 Jun. 30 2022  -0.28       -0.28      -0.20     Beat    29​
 Mar. 31 2022  -0.23       -0.22      -0.32     Missed  -42.9
 ​​Dec.        -0.27       -0.24      -0.22     Beat    9
 31 2021                                                
 Sep. 30 2021  -0.20       -0.20      -0.24     Missed  -17.1​
 Jun. 30 2021  -0.17       -0.17      -0.03     Beat    82.8
 Mar. 31 2021  -0.17       -0.19      -0.14     Beat    25.3
 This summary was machine generated May 12 at 18:18 GMT.  All
figures in US dollars  unless otherwise stated